CDK8 and neoplasm: This analysis suggested an increase in tumor-associated myocytes that occurred in everolimus-adapted tumors and was counteracted by CDK8/19i, which could reflect changes in tumor invasion of the muscle layer, which was previously shown to be inhibited by CDK8/19i (32).